Lappe Mark
Chief Executive Officer
Lappe Mark has filed 1 SEC Form 4 filing (6 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.
On the most recent filing, Lappe Mark is listed as Chief Executive Officer at Inhibrx Biosciences, Inc. Inside the rolling window, Lappe Mark reported 1 open-market purchase totaling $2.6M in INBX and no open-market sales.
Companies traded
Other insiders at INBX
Insider Buying
$2.6M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lappe Mark made?
Lappe Mark has filed 1 SEC Form 4 filing (6 transaction rows) across 1 company since 2026.
Which companies does Lappe Mark trade?
Lappe Mark has filed SEC Form 4 disclosures for 1 company, including INBX.
When was Lappe Mark's most recent SEC Form 4 filing?
Lappe Mark's most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.
What is Lappe Mark's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lappe Mark is listed as Chief Executive Officer.
What is Lappe Mark's total buy and sell value in the current window?
Inside the rolling retention window, Lappe Mark bought $2.6M and sold $0 based on SEC Form 4 filings.
What was Lappe Mark's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 25,000 INBX shares on 2026-09-08, worth $2.6M, per SEC Form 4 filings.